Large B cell lymphoma microenvironment archetype profiles.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Xubin, Singhal Kartik, Deng Qing, Chihara Dai, Russler-Germain David, Harkins R Andrew, Henderson Jared, Arita Kotaro, Kizhakeyil Atish, Sun Ryan, Lakra Priya, Hussein Usama, Foltz Jennifer A, Wilson Ashley, Schmidt Evelyn, Nizamuddin Imran, Dinh Tommy, Kesaraju Akhil, Hamilton Mark P, Allen Carl, Gandhi Maher K, Tobin Joshua, Jiang Aixiang, Hilton Laura, Scott David W, Vega Francisco, Flowers Christopher R, Westin Jason R, Griffith Obi L, Fehniger Todd A, Griffith Malachi, Green Michael R
Аннотация
Large B cell lymphomas (LBCL) are clinically and biologically heterogeneous lymphoid malignancies with complex microenvironments that are central to disease etiology. Here, we have employed single-nucleus multiome profiling of 232 tumor and control biopsies to characterize diverse cell types and subsets that are present in LBCL tumors, effectively capturing the lymphoid, myeloid, and non-hematopoietic cell compartments. Cell subsets co-occurred in stereotypical lymphoma microenvironment archetype profiles (LymphoMAPs) defined by; (1) a sparsity of T cells and high frequencies of cancer-associated fibroblasts and tumor-associated macrophages (FMAC); (2) lymph node architectural cell types with naive and memory T cells (LN); or (3) activated macrophages and exhausted CD8+ T cells (TEX). Divergent patterns of cell-cell communication underpinned the transcriptional phenotypes of archetype-defining cell subsets resulting in exclusion, support, or suppression of T cells, respectively. Consistent with this, LymphoMAPs were associated with significantly different clinical outcomes following CD19 chimeric antigen receptor (CAR) T cell therapy.